-
BMS 309403: FABP4 Inhibitor Workflow
2026-09-04
BMS 309403 provides a potent, selective way to interrogate FABP4-driven lipid handling, macrophage inflammation, and foam-cell formation. This workflow connects mechanistic pathway mapping with practical cell-based assays for atherosclerosis and metabolic disease research.
-
CDELNs Protect Sertoli Cells in Testicular Injury
2026-09-04
The reference study identifies Cistanche deserticola-derived exosome-like nanovesicles as a potential intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that vesicle-delivered miR159b-3p reduces P21-mediated cell cycle arrest in Sertoli cells and promotes CDK1 activation, while human single-cell data support the relevance of the Sertoli cell–P21 axis to non-obstructive azoospermia.
-
Protease Inhibitor Cocktail for Dual-Genome OXPHOS Assays
2026-09-04
The Protease Inhibitor Cocktail supports controlled protein preservation in LRPPRC–dasatinib OXPHOS studies. This guide explains how an EDTA-Free Protease Inhibitor improves assay interpretation without confusing protein stability with biological pathway inhibition.
-
Gentamycin Sulfate: From Ribosome to Resistance
2026-09-03
A translational framework for using Gentamycin Sulfate to connect ribosome biology, bacterial protein synthesis research, resistance modeling, and the evolving landscape of drug-resistant Gram-negative pathogens.
-
Ouabain: Assay Design for Na+/K+-ATPase Studies
2026-09-02
Ouabain provides a precise way to perturb extracellular Na+/K+-ATPase activity while tracking downstream sodium, calcium, viability, and contractile responses. This guide translates that mechanism into reproducible cell-based workflows, cardiovascular research designs, and troubleshooting strategies informed by quantitative assay principles.
-
Elbasvir–Grazoprevir: Evidence for HCV Treatment
2026-09-02
The reference review explains why combining the NS5A inhibitor elbasvir with the NS3/4A protease inhibitor grazoprevir provides complementary blockade of the HCV life cycle. Its synthesis of pharmacology, clinical efficacy, safety, resistance, and special-population data supports a focused role in genotype 1 and 4 disease, while also clarifying the limits of translating in vitro potency into clinical decisions.
-
Caspase-3 Fluorometric Assay Kit in RCC
2026-09-01
The Caspase-3 Fluorometric Assay Kit provides a quantitative way to connect DEVD-dependent enzyme activity with apoptotic mechanism. This guide uses renal cell carcinoma research to explain assay design, controls, interpretation, and limitations.
-
Nanoparticle Uptake by Human Corneal Epithelial Cells
2026-09-01
Azadi and David examined how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells in a mucosa-aware in vitro model. Their findings identify energy-dependent endocytosis, particularly macropinocytosis and caveolae-mediated uptake, as central mechanisms and provide practical design guidance for topical ocular nanomedicines.
-
L-Glutathione Reduced in Redox Assays
2026-08-31
L-Glutathione Reduced is more than a generic antioxidant: it is a mechanistically informative reagent for redox, GST, and cancer-metabolism workflows. This guide connects glutathione chemistry with GOT1 research to improve assay controls, interpretation, and experimental reproducibility.
-
Dual-Action Inhibitors Tune p38α Dephosphorylation
2026-08-31
The reference preprint shows that some kinase inhibitors do more than occupy the p38α catalytic site: they also stabilize an activation-loop conformation that exposes phospho-threonine to the WIP1 phosphatase. This structure-guided mechanism offers a framework for interpreting p38 inhibition through both catalytic blockade and accelerated molecular reset.
-
Substrate Stiffness, FAK, and Dentinogenesis
2026-08-30
This study identifies a LAMB1–FAK–MEK1/2 signaling axis that links substrate stiffness to odontoblast-like cell extension and dentinogenic differentiation. Its findings support a mechanistic framework for designing cell–material interfaces in reparative dentin and dental tissue engineering.
-
Estradiol Benzoate Assay Workflows
2026-08-29
Build more reproducible ERα binding and signaling experiments with a high-purity synthetic estradiol analog. This guide connects practical stock preparation, quantitative assay design, cross-species receptor testing, and troubleshooting to defensible estrogen receptor research.
-
Griseofulvin in Microtubule Mechanism Assays
2026-08-28
Use Griseofulvin as a DMSO-compatible microtubule probe for fungal cell studies, viability experiments, and mechanism-focused aneugen screening. This workflow separates broad cytotoxicity from microtubule disruption by combining timed exposure, flow-cytometry biomarkers, and orthogonal controls.
-
GANT61 Workflows for GLI-Driven Cancer Research
2026-08-28
GANT61 is a practical GLI inhibitor for testing whether GLI1/2 activity sustains malignant growth, ferroptosis resistance, or cisplatin insensitivity. This workflow connects pathway-level pharmacology with GLI2–PRDX1 validation in bladder cancer and provides formulation, dosing, and troubleshooting guidance for translational cancer research.
-
Merbromin as a Selective SARS-CoV-2 3CLpro Inhibitor
2026-08-27
Chen and colleagues identified Merbromin as a selective in vitro inhibitor of the SARS-CoV-2 chymotrypsin-like protease 3CLpro through screening of approximately 6,000 compounds. Kinetic, binding, and docking analyses supported a mixed-type inhibition model involving more than one interaction site, providing a mechanistic starting point for antiviral inhibitor development.